Immunology and Bi...
Follow
Find tag "#antibody drug conjugate"
8.7K views | +0 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Philogen :: innovating targeting ::

Philogen :: innovating targeting :: | Immunology and Biotherapies | Scoop.it

Philochem owns five antibody libraries (ETH2-GOLD, PHILO-1, PHILO-2, PHILO-DIAMOND and PHILOtop) that contain over 30 billion different binding specificities.

Philochem’s human antibody libraries (ETH2-GOLD, PHILO-1, PHILO-2 and PHILO-DIAMOND) have been used to generate high-quality binding specificities against >50 different antigens, including human monoclonal antibodies which are currently being developed in clinical trials by Philogen.

 

Philochem’s antibody libraries contain monoclonal antibodies in scFv format. Once monoclonal antibodies which are specific to the target antigen of choice are isolated, they can be easily reformatted into other recombinant antibody formats (e.g., IgG, Fab, mini-antibody, Fc-fusion) using general vectors and well-established procedures which are available at Philochem.


Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 8:38 AM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.

 

Scooped by Gilbert Faure au nom de l'ASSIM from PARP Inhibitors Cancer Review
Scoop.it!

PSMA ADC Produces Clinically Relevant Declines in PSA and CTC counts and Radiologic Response – ADC Review

Full results from a Phase II clinical trial of PSMA ADC (Progenics Pharmaceuticals, Inc., Tarrytown, NY, USA), a fully human monoclonal antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC) presented at ...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 4, 2:35 AM

PSMA ADC is fully human IgG1 antibody designed to delivers the chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of the prostate specific membrane antigen or PSMA, a protein that is a clinically validated biomarker of prostate cancer and which is overexpressed on the surface of prostate cancer cells.

 

The PSMA antibody is linked to the chemotherapeutic microtubule disrupting agent monomethyl auristatin E (MMAE), which inhibits cell proliferation by disrupting the cellular “backbone” required for replication. The resultant antibody-drug conjugate attaches itself to the PSMA-protein on the surface of prostate cancer cells and is designed to internalize into the cancer cell, release the active anti-cancer drug, and destroy the malignant cell.